|
Play Video: The Importance of Insider Buying
|
|
|
The table below summarizes the most recent Prelude Therapeutics insider buying information, with links below the price to see the
CAGR achieved by each insider on their purchases. As the saying goes on Wall St., there are many
possible reasons to sell a stock, but only one reason to buy. Watch the importance of insider buying video for more
information about why Prelude Therapeutics insider buys are important for investors to follow.
Date | Insider | Price | Amount |
5-22-2023 Insider Buy |
David P. Bonita Director and >10% Owner |
$5.75
CAGR »
|
$4,999,998.75 869,565 shares |
5-22-2023 Insider Buy |
ORBIMED ADVISORS LLC Director and >10% Owner |
$5.75
CAGR »
|
$4,999,998.75 869,565 shares |
12-20-2022 Insider Buy |
Krishna Vaddi CEO |
$5.13
CAGR »
|
$98,445.95 19,188 shares |
12-8-2022 Insider Buy |
Laurent Chardonnet Chief Financial Officer |
$4.76
CAGR »
|
$47,600.00 10,000 shares |
12-14-2021 Insider Buy |
Andrew Combs EVP, Head of Chemistry |
$11.86
CAGR »
|
$94,880.00 8,000 shares |
9-29-2020 Insider Buy |
David P. Bonita Director and >10% Owner |
$19.00
CAGR »
|
$23,499,200.00 1,236,800 shares |
9-29-2020 Insider Buy |
BROS. Advisors LP Baker Director and >10% Owner |
$19.00
CAGR »
|
$29,999,993.00 1,578,947 shares |
9-29-2020 Insider Buy |
Christopher Pierce EVP and Chief of Business Oper |
$19.00
CAGR »
|
$71,250.00 3,750 shares |
9-29-2020 Insider Buy |
Deborah Morosini EVP, Chief of Clinical Affairs |
$19.00
CAGR »
|
$8,436.00 444 shares |
9-29-2020 Insider Buy |
Mardi Dier Director |
$19.00
CAGR »
|
$190,000.00 10,000 shares |
9-29-2020 Insider Buy |
Andrew Combs EVP, Head of Chemistry |
$19.00
CAGR »
|
$19,000.00 1,000 shares |
Also See: Institutional Holders of PRLD
Also See: SEC filings
Below we present the annualized performance delivered by Prelude Therapeutics stock since 5-22-2023 (the date of the most recent
insider purchase). The performance of the investment from the time Prelude Therapeutics insider buying occurred is the ultimate
test of whether insiders were right about PRLD being a good buy.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
05/23/2023 |
|
End date: |
04/17/2024 |
|
Start price/share: |
$5.45 |
|
End price/share: |
$4.18 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-23.30% |
|
Annualized Gain: |
-25.77% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$7,670.00 |
|
Years: |
0.90 |
|
Prelude Therapeutics Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.),
and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these
categories, but instead file their holdings quarterly on the latest form 13F filings.
While recent Prelude Therapeutics insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding PRLD
|
|